Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker

Abstract

Improved biomarkers are needed for early cancer detection, risk stratification, treatment selection, and monitoring treatment response. Although proteins can be useful blood-based biomarkers, many have limited sensitivity or specificity for these applications. Long INterspersed Element-1 (LINE-1) open reading frame 1 protein (ORF1p) is a transposable element protein overexpressed in carcinomas and high-risk precursors during carcinogenesis with negligible expression in normal tissues, suggesting ORF1p could be a highly specific cancer biomarker. To explore ORF1p as a blood-based biomarker, we engineered ultrasensitive digital immunoassays that detect mid-attomolar (10−17 mol/L) ORF1p concentrations in plasma across multiple cancers with high specificity. Plasma ORF1p shows promise for early detection of ovarian cancer, improves diagnostic performance in a multianalyte panel, provides early therapeutic response monitoring in gastroesophageal cancers, and is prognostic for overall survival in gastroesophageal and colorectal cancers. Together, these observations nominate ORF1p as a multicancer biomarker with potential utility for disease detection and monitoring.

Significance:

The LINE-1 ORF1p transposon protein is pervasively expressed in many cancers and is a highly specific biomarker of multiple common, lethal carcinomas and their high-risk precursors in tissue and blood. Ultrasensitive ORF1p assays from as little as 25 μL plasma are novel, rapid, cost-effective tools in cancer detection and monitoring.

See related commentary by Doucet and Cristofari, p. 2502.

This article is featured in Selected Articles from This Issue, p. 2489

Funding
Reverse transcriptase inhibitor effects on the mobilome of colon cancerOrganoid, Mouse Model, and BiomarkerDevelopment of an Ultrasensitive Point-of-Care Salivary Diagnostic for Mild Traumatic Brain InjuryConsequences of retrotransposition on genome integrityProject 3: Investigating new treatment approaches based on DNA repair vulnerability in ARID1A mutated type I ovarian cancerMolecular Immunology and Tumor BiologyAdministrative CoreCharacterizing the LINE-1 Retrotransposition-Replication ConflictA Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor ImmunityDana Farber/ Harvard Cancer Center SPORE in Gastrointestinal CancerDevelopmental FundsTR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsExpression and Impact of Interspersed RepeatsElucidating structural, mechanistic, and allosteric determinants of mTOR Complex 2 (mTORC2) signaling.Proteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker DiscoveryAn integrated pipeline for next-generation protein interactomicsLung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in BloodExpression and Impact of Interspersed RepeatsElucidating structural, mechanistic, and allosteric determinants of mTOR Complex 2 (mTORC2) signaling.Development of an Ultrasensitive Point-of-Care Salivary Diagnostic for Mild Traumatic Brain InjuryReverse transcriptase inhibitor effects on the mobilome of colon cancerA Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor ImmunityTR&D Project 4. The Imaging Stage: Multiscale Spatiotemporal Modeling of Macromolecular Systems in Cellular NeighborhoodsMolecular Immunology and Tumor BiologyLung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in BloodAdministrative CoreProteomic, Genomic, and Longitudinal Pathways to Ovarian Cancer Biomarker DiscoveryAn integrated pipeline for next-generation protein interactomicsNational Institutes of Health Grant P50CA228991 Ovarian SPORENational Institutes of Health Grant P30CA006516 IncubatorBreak Through Cancer FundingFriends For an Earlier Breast Cancer Test FundingMinnesota Ovarian Cancer Alliance FundingU.S. Department of Defense Grant W81XWH-22-1-0852Canary Foundation FundingGray Foundation FundingThe Concord (MA) Detect Ovarian Cancer Early Fund FundingGood Ventures Foundation FundingFriends of Dana-Farber Cancer Institute FundingDana-Farber Cancer Institute FundingDana-Farber/Harvard Cancer Center FundingACD-Biotechne FundingRobert L. Fine Cancer Research Foundation FundingWorldwide Cancer Research Grant 19-0223Robertson Therapeutic Development Fund FundingNile Albright Research Foundation FundingVincent Memorial Research Foundation FundingStand Up To Cancer Grant Gastric Cancer Interception Research Team Grant (SU2C-AACR-DT-30-20)National Institutes of Health Grant P50CA240243 ovarian SPORE

NCI NIH HHS

R01 CA240924

NCI NIH HHS

P50 CA240243

NIBIB NIH HHS

F32 EB029777

NCI NIH HHS

R01 CA276112

NCI NIH HHS

P50 CA228991

NCI NIH HHS

T32 CA009216

NCI NIH HHS

U2C CA271871

NCI NIH HHS

R01 CA240816

NCI NIH HHS

U01 CA228963

NCI NIH HHS

P50 CA127003

NCI NIH HHS

P30 CA006516

NIGMS NIH HHS

P41 GM109824

NIGMS NIH HHS

R01 GM130680

NIDDK NIH HHS

K08 DK129824

NCI NIH HHS

U01 CA152990

NIGMS NIH HHS

R01 GM126170

NCI NIH HHS

U01 CA233364

National Institutes of Health

R01GM130680

National Institutes of Health

K08DK129824

National Institutes of Health

F32EB029777

National Institutes of Health

R01CA240924

National Institutes of Health

U01CA228963

National Institutes of Health

P41GM109824

National Institutes of Health

T32CA009216

National Institutes of Health

U01CA233364

National Institutes of Health

U2CCA271871

National Institutes of Health

U01CA152990

National Institutes of Health

R01GM126170